Highly Tumorigenic Hepatocellular Carcinoma Cell Line with Cancer Stem Cell-like Properties

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Feb 3

PMID 28152020

Citations 27

Authors

Benoit Lacoste

Valerie-Ann Raymond

Shamir Cassim

Pascal Lapierre

Marc Bilodeau

Affiliations

Soon will be listed here.

Abstract

There are limited numbers of models to study hepatocellular carcinoma (HCC) in vivo in immunocompetent hosts. In an effort to develop a cell line with improved tumorigenicity, we derived a new cell line from Hepa1-6 cells through an in vivo passage in C57BL/6 mice. The resulting Dt81Hepa1-6 cell line showed enhanced tumorigenicity compared to Hepa1-6 with more frequent (28±12 vs. 0±0 lesions at 21 days) and more rapid tumor development (21 (100%) vs. 70 days (10%)) in C57BL/6 mice. The minimal Dt81Hepa1-6 cell number required to obtain visible tumors was 100,000 cells. The Dt81Hepa1-6 cell line showed high hepatotropism with subcutaneous injection leading to liver tumors without development of tumors in lungs or spleen. In vitro, Dt81Hepa1-6 cells showed increased anchorage-independent growth (34.7±6.8 vs. 12.3±3.3 colonies; P<0.05) and increased EpCAM (8.7±1.1 folds; P<0.01) and β-catenin (5.4±1.0 folds; P<0.01) expression. A significant proportion of Dt81Hepa1-6 cells expressed EpCAM compared to Hepa1-6 (34.8±1.1% vs 0.9±0.13%; P<0.001). Enriched EpCAM+ Dt81Hepa1-6 cells led to higher tumor load than EpCAM- Dt81Hepa1-6 cells (1093±74 vs 473±100 tumors; P<0.01). The in vivo selected Dt81Hepa1-6 cell line shows high liver specificity and increased tumorigenicity compared to Hepa1-6 cells. These properties are associated with increased expression of EpCAM and β-catenin confirming that EpCAM+ HCC cells comprise a subset with characteristics of tumor-initiating cells with stem/progenitor cell features. The Dt81Hepa1-6 cell line with its cancer stem cell-like properties will be a useful tool for the study of hepatocellular carcinoma in vivo.

Citing Articles

Invariant NK T cells counteract HCC metastasis by mediating the migration of splenic CD4 T cells into the white pulp and infiltration of B cells.

Geng J, Xie M, Yan M, Xie X, Wang F, Zhu R Commun Biol. 2025; 8(1):351.

PMID: 40033139 PMC: 11876620. DOI: 10.1038/s42003-025-07798-2.

Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.

Tambay V, Raymond V, Voisin L, Meloche S, Bilodeau M Int J Mol Sci. 2024; 25(14).

PMID: 39062801 PMC: 11277143. DOI: 10.3390/ijms25147558.

Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma.

Voisin L, Lapouge M, Saba-El-Leil M, Gombos M, Javary J, Trinh V Dis Model Mech. 2024; 17(7).

PMID: 39051113 PMC: 11552496. DOI: 10.1242/dmm.050553.

Effects of Dopamine on stem cells and its potential roles in the treatment of inflammatory disorders: a narrative review.

Liu G, Liu Z, Lin Z, Chen P, Yan Y, Lin Q Stem Cell Res Ther. 2023; 14(1):230.

PMID: 37649087 PMC: 10469852. DOI: 10.1186/s13287-023-03454-w.

ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism.

Sun L, Suo C, Zhang T, Shen S, Gu X, Qiu S Nat Chem Biol. 2023; 19(12):1492-1503.

PMID: 37500770 DOI: 10.1038/s41589-023-01391-6.

References

Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T . CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood. 1997; 90(6):2217-33. View

Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U . EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene. 2012; 32(5):641-50. DOI: 10.1038/onc.2012.75. View

Mamo S, Gal A, Bodo S, Dinnyes A . Quantitative evaluation and selection of reference genes in mouse oocytes and embryos cultured in vivo and in vitro. BMC Dev Biol. 2007; 7:14. PMC: 1832186. DOI: 10.1186/1471-213X-7-14. View

Munz M, Baeuerle P, Gires O . The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009; 69(14):5627-9. DOI: 10.1158/0008-5472.CAN-09-0654. View

Yamashita T, Forgues M, Wang W, Kim J, Ye Q, Jia H . EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68(5):1451-61. DOI: 10.1158/0008-5472.CAN-07-6013. View

Figueiredo M, Wentworth K, Sandgren E . Quantifying growth and transformation frequency of oncogene-expressing mouse hepatocytes in vivo. Hepatology. 2010; 52(2):634-43. DOI: 10.1002/hep.23682. View

Yamashita T, Budhu A, Forgues M, Wang X . Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007; 67(22):10831-9. DOI: 10.1158/0008-5472.CAN-07-0908. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Whiteside T, Mandapathil M, Szczepanski M, Szajnik M . Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer. 2011; 98(2):E25-31. DOI: 10.1684/bdc.2010.1294. View

10.

Whittaker S, Marais R, Zhu A . The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989-5005. DOI: 10.1038/onc.2010.236. View

11.

Vineis P, Schatzkin A, Potter J . Models of carcinogenesis: an overview. Carcinogenesis. 2010; 31(10):1703-9. PMC: 3025741. DOI: 10.1093/carcin/bgq087. View

12.

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

13.

Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao W . CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci. 2012; 8(7):992-1004. PMC: 3421230. DOI: 10.7150/ijbs.4454. View

14.

Curley M, Therrien V, Cummings C, Sergent P, Koulouris C, Friel A . CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009; 27(12):2875-83. DOI: 10.1002/stem.236. View

15.

Boterberg T, Bracke M, Bruyneel E, Mareel M . Cell aggregation assays. Methods Mol Med. 2011; 58:33-45. DOI: 10.1385/1-59259-137-X:033. View

16.

Darlington G, Bernhard H, Miller R, Ruddle F . Expression of liver phenotypes in cultured mouse hepatoma cells. J Natl Cancer Inst. 1980; 64(4):809-19. View

17.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang H . EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136(3):1012-24. PMC: 2828822. DOI: 10.1053/j.gastro.2008.12.004. View

18.

Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H . CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 2009; 101(1):112-9. PMC: 11159715. DOI: 10.1111/j.1349-7006.2009.01370.x. View

19.

Li Y, Tian B, Yang J, Zhao L, Wu X, Ye S . Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol. 2004; 130(8):460-8. DOI: 10.1007/s00432-004-0564-9. View

20.

Qian Y, Chen Y, Yang W, Fu J, Cao J, Ren Y . p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis. Gastroenterology. 2012; 142(7):1547-58.e14. DOI: 10.1053/j.gastro.2012.02.042. View